Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis.

MLA

Launay, Manon, et al. “Can We Identify Patients Carrying Targeted Deleterious DPYD Variants with Plasma Uracil and Dihydrouracil? A GPCO-RNPGx Retrospective Analysis.” Clinical Chemistry and Laboratory Medicine, vol. 62, no. 12, June 2024, pp. 2415–24. EBSCOhost, https://doi.org/10.1515/cclm-2024-0317.

APA

Launay, M., Raymond, L., Guitton, J., Loriot, M.-A., Chatelut, E., Haufroid, V., Thomas, F., & Etienne-Grimaldi, M.-C. (2024). Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis. Clinical Chemistry and Laboratory Medicine, 62(12), 2415–2424. https://doi.org/10.1515/cclm-2024-0317

Chicago

Launay, Manon, Laure Raymond, Jérôme Guitton, Marie-Anne Loriot, Etienne Chatelut, Vincent Haufroid, Fabienne Thomas, and Marie-Christine Etienne-Grimaldi. 2024. “Can We Identify Patients Carrying Targeted Deleterious DPYD Variants with Plasma Uracil and Dihydrouracil? A GPCO-RNPGx Retrospective Analysis.” Clinical Chemistry and Laboratory Medicine 62 (12): 2415–24. doi:10.1515/cclm-2024-0317.